“Tim is a weird-science guy." A 74-year-old professor at Harvard Medical School and a research lab chief at Boston Children’s Hospital is a heads-down scientist and entrepreneur with some notable quirks.
Moderna said Wednesday that using a new version of its Covid-19 vaccine as a booster led to a superior antibody response against the Omicron variant compared to its current shot.
The federal government has distributed Covid-19 vaccines and treatments for free so far, but most likely, the handouts won’t last forever.
The CEO of Seagen, formerly known as Seattle Genetics, is on a leave of absence following an alleged incident of domestic violence.
Moderna is poised to make strides in mRNA vaccines for diseases ranging from flu to HIV to cancer. But scientific and economic hurdles make success far from guaranteed.
Read all 400 pages of the White House’s binder of Covid-19 funding documents, made public for the first time.
Who's going to run Biogen? Does Aduhelm have a future? And is it OK to shame reporters? We cover all that and more this week on “The Readout LOUD.” Listen now:
New data from Moderna offer hope that booster shots against Covid-19 could become at least somewhat more effective than they already are.
Moderna announced it will ask the FDA to authorize its Covid-19 vaccine for emergency use in children aged 6 months to 6 years, a group for which there are currently no authorized Covid vaccines.
Moderna said it will not seek to enforce its patents on its Covid-19 vaccine in low- to middle-income countries — but will do so in wealthier nations.
Moderna has applied for patents in South Africa relating to its Covid-19 vaccine, prompting fears the company could seek to prevent an African vaccine hub from making its own version.
The success of the Spikevax mRNA vaccine against Covid-19 — it ended up in 73 million American arms by the end of 2021 — sent Moderna’s stock soaring. And that turned Bancel into a multibillionaire and one of the world’s most influential biotech CEOs. Previously CEO of a French diagnostics company, Bancel has led Moderna…
When it comes to drug development, the health care industry must embrace its learnings with Covid-19: good drugs need good science and good science thrives on collaboration.
A new study conducted in primates suggests there may not be a benefit from updating Covid-19 vaccines to target the Omicron variant at this time.
The FDA granted full approval to Moderna’s Covid-19 vaccine on Monday, making it the country’s second fully licensed vaccine to protect against SARS-CoV-2.
"There’s a high probability we will have another variant coming up. The question is when and will it be less dangerous?"
Moderna (MRNA) disclosed that a booster shot of its coronavirus vaccine significantly raises the level of antibodies that can thwart the Omicron variant.
Moderna predicts that existing Covid-19 vaccines will be less effective against Omicron than they have been against the Delta variant.
Vaccine makers will spend several weeks assessing the danger and potential impact of the new Omicron variant of Covid-19, but they're already developing ways to combat it.
In just a few years, Moderna went from stock market dud to moonshot, a prime example of how Massachusetts’ life sciences and tech companies can create wealth that ripples through the local economy.
The Moderna scientists, engineers, and staff who worked to deliver a modern-day miracle — a vaccine against Covid-19 — are to be commended. Now the company needs to do its part to help end the pandemic in low-income countries.
Pfizer raised the full-year sales forecast for its Covid-19 vaccine by 7.5% to $36 billion, as it signs deals with countries for booster doses.
Moderna, flush with cash thanks to its blockbuster Covid-19 vaccine, has picked a partner for its foray into CRISPR, and it’s not one of the field’s multibillion-dollar players.
Though developing a safe and effective Covid-19 vaccine in a timeline that many called impossible was a monumental effort, the Moderna story is a stark reminder of how thin the line can be between success and failure.
Follow along today as STAT's @HelenBranswell and @matthewherper live blog the FDA advisory committee meeting on Moderna's Covid vaccine booster.
Moderna announced plans to build a plant to manufacture Covid-19 vaccines in Africa. But some critics say it isn't enough to ensure access.
Founders and investors have been allowed to bend the course of the pandemic to their private benefit. When a few people win big, everyone else loses.
Moderna chief executive Stephane Bancel shrugged off the Biden administration’s support for suspending patents for coronavirus vaccines.
The federal government has now invested about $6 billion in the Covid-19 vaccine from Moderna, the Cambridge, Mass., biotech that few outside the scientific and investment worlds had heard of a couple of years ago.
